GLA-SE

Phase 2Biologic

Merck & Co.

GLA-SE is one of 66 biologic programs targeting Schistosomiasis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SchistosomiasisActive, not recruiting

MalariaActive, not recruiting

Merkel Cell CarcinomaActive, not recruiting

SchistosomiasisPhase 2

Active, not recruiting

MalariaPhase 1

Active, not recruiting

Merkel Cell CarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

479 competitors in Malaria

#DrugCompanyPhaseTrials

GLA-SE

Merck & Co.

Phase 2

2 2

Biltricide

Bayer

Preclinical

1 3

Stelara

Johnson & Johnson

Preclinical

—4

Hydroxychloroquine Sulfate

Novartis

Preclinical

—5

Iron

WWatson Pharmaceuticals

Preclinical

1 6

IV LBH589

Novartis

Preclinical

1 7

IV Ceftriaxone

RRESnTEC, Institute of Research

Preclinical

1 8

Mefloquine Plus Artesunate

Medicines for Malaria Venture

Preclinical

1 9

RTS,S/AS01E

GSK

Preclinical

4 10

Piperaquine

UUniversity of Oxford

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Malaria2 trials

Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Variously Adjuvanted

Completed·UUniversity Hospital Tuebingen·Phase 1·NCT02647489·66 enrolled

Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults

Completed·IInstitut National de la Santé Et de la Recherche Médicale, France·Phase 1·NCT02658253·68 enrolled

Immunogenicity2 trials

Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT02508376·70 enrolled

Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Chimp Adenovirus Vaccines Expressing Clade C gp140 & CH505TF gp120 Protein Boost in HIV-uninfected Adult.

Completed·HHIV Vaccine Trials Network·Phase 1·NCT05182125·34 enrolled

Chemotherapy1 trial

Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy

Withdrawn·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1·NCT03982121

Merkel Cell Carcinoma1 trial

A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT02035657·10 enrolled

Vaccine1 trial

LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT01751048·48 enrolled

3 more indications

Schistosomiasis1 trial

Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children

Completed·OOswaldo Cruz Foundation·Phase 2·NCT03799510·95 enrolled

Immune Response1 trial

Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions

Completed·OOswaldo Cruz Foundation·Phase 2·NCT03041766·30 enrolled

Unspecified2 trials

The Effects of GLA (5 mcg) on Human Volunteers

Completed·AAccess to Advanced Health Institute (AAHI)·Phase 1·NCT01864876·17 enrolled

The Effects of GLA on Human Volunteers

Completed·RRockefeller University·Phase 1·NCT01397604·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for GLA-SE. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GLA-SE compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GLA-SE. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

GLA-SE

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Malaria2 trials

Immunogenicity2 trials

Chemotherapy1 trial

Merkel Cell Carcinoma1 trial

Vaccine1 trial

Schistosomiasis1 trial

Immune Response1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News